权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Microarray Chips for Rapid Detection of High Affinity Nucleic Acid Sequences.

用于快速检测高亲和力核酸序列的微阵列芯片。

基本信息

批准号：
7482692
负责人：
Mark Patrick McPike
金额：
$ 64.59万
依托单位：
APTAMATRIX, INC.
依托单位国家：
美国
项目类别：
财政年份：
2006
资助国家：
美国
起止时间：
2006-08-01 至 2010-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7482692
关键词：
Affinity Amino Acid Sequence Animals Antibodies Antigens Area Base Sequence Binding Binding Proteins Biological Assay Biological Factors Bioterrorism Capillary Electrophoresis Cations Cell Line Classification Cloning Cryptosporidium DNA Diagnostic Engineering Event Gel Genetic Transcription Hand Image Kinetics Label Legal patent Libraries Licensing Life Marketing Measures Melanocytic nevus Methods Mole the mammal Molecular Probes Monoclonal Antibodies Nucleic Acid Probes Nucleic Acids Nucleic acid sequencing Nucleotides Oligonucleotides Optics Organism Peptide Sequence Determination Peptides Pharmacotherapy Phase Population Process Protein Array Proteins Protocols documentation Public Health RNA Resolution Reverse Transcription Screening procedure Set protein Signal Transduction Specificity Structure Surface Techniques Technology Time Work aptamer base biochip cellular targeting cofactor combinatorial commercialization concept design drug development drug discovery interest mimetics point of care pressure rapid detection sensor size stem

项目摘要

DESCRIPTION (provided by applicant): This Phase II project aims at further advancing and commercializing a microarray-based screening approach, for discovering nucleic acid probes that have high affinity and high specificity for protein and cellular targets. Oligonucleotides discovered in these screens can be engineered into sensors having exquisite sensitivity and selectivity for drug development, environmental sensing and POC-diagnostics; areas currently dominated by antibody based technologies. In Phase II we plan to pursue protein targets that are relevant to each of these market segments, in an effort streamline the commercialization process and establish a broad product portfolio. PUBLIC HEALTH RELEVANCE: The Combigen screening process being further developed in this phase II project will create molecular probes that specifically bind protein based targets. These probes will find applications in environmental sensing, point-of-care diagnostics and drug therapies.

描述（由申请人提供）：该二期项目旨在进一步推进和商业化基于微阵列的筛选方法，以发现对蛋白质和细胞靶点具有高亲和力和高特异性的核酸探针。在这些筛选中发现的寡核苷酸可以设计成具有灵敏度和选择性的传感器，用于药物开发，环境传感和poc诊断；目前以抗体技术为主导的领域。在第二阶段，我们计划追求与这些细分市场相关的蛋白质目标，努力简化商业化过程并建立广泛的产品组合。